Alzheimer Vaccine ALZ-101 Shows Safety, Oligomer-Specific Humoral Immune Response in Early-Stage Trial
Data from a phase 1b trial (ALZ-C-001; NCT05328115) revealed that ALZ-101, a vaccine developed by Alzinova, was safe in patients with mild Alzheimer disease (AD) or mild cognitive impairment (MCI) due to AD. The vaccine produced an amyloid-ß oligomer- …